Member Info for desamax

*sar bod

Maybe the sat bod are waiting for this to be fixed before they issue the expected RNS LOL

Tweeted this today

Our technical team will be testing a few fixes today in the hope of getting RNS releases showing for tomorrow if all goes well. We will update once we've made some progress.

This link shows Gates have been involved in Tyk2 for many years. Sar whit it’s latest research, must tick many boxes for the foundation to potentially back the research moving forward.

https://rupress.org/jem/article/212/10/1641/41672/Human-TYK2-deficiency-Mycobacterial-and-viral

Taken from the UKRI report Seem to mirror T2 link.??

Results of Competition: UKRI Ideas to Address COVID-19: Innovate UK de minimis Aug 2020
Competition Code: 2007_UKRI_IDEAS_COVID19_OPEN_DEMINIMIS
Total available funding is £120m

Investigating the therapeutic potential of TYK2 / JAK1 inhibitor SDC-1801 in severe phase Covid-19
https://www.gov.uk/government/publications/innovate-uk-funded-projects

Project description - provided by applicants
Sareum is developing SDC-1801, a small-molecule inhibitor of kinases TYK2 and JAK1, as a potential therapeutic for a wide range of inflammatory diseases such as psoriasis, lupus and Crohn's disease. Cells signal to each other using cytokines, and SDC-1801 works by blocking specific cytokine signalling pathways, leading to reduced inflammation.
Covid-19 is caused by the virus SARS-CoV-2, and usually results in a mild disease that resolves on its own. However, some patients develop a potentially fatal severe disease due to inflammation arising from a 'cytokine storm' overreaction of the immune system leading to Acute Respiratory Distress Syndrome (ARDS), requiring intensive care. A major inflammatory pathway over activated in severe Covid-19 patients, known as Interferon Type 1, is blocked by SDC-1801\. We believe that SDC-1801 could therefore benefit severe phase Covid-19 patients by blocking Interferon Type 1 signals and reducing the inflammation during 'cytokine storm'.
Furthermore, inhibiting the kinase TYK2 has been shown to reduce bacterial pneumonia in influenza patients. We believe SDC-1801 will have the same effect in Covid-19 patients, potentially reducing the levels of bacterial infection that have been seen in up to 50% of Covid-19 patients.
The aim of this research is to investigate the effects of SDC-1801 on cytokine signalling after human cells are infected with SARS-CoV-2 to ensure that the Interferon Type 1 pathway can be blocked in this disease. We will also use mouse models to investigate whether SDC-1801 can reduce bacterial

Where is everyone we just turned blue lol

https://www.whatdotheyknow.com/request/investigating_the_therapeutic_po

Dear UK Research and Innovation,

The Project Status in respect of the captioned study indicates that the study is now 'Closed'. (https://gtr.ukri.org/projects?ref=83721)

Please provide:

1) copies of all reports, communications and correspondence relating to the outcomes of the study,
2) copy of the final outturn report,
3) details of any further potential follow-on studies involving UKRI in respect of SDC-1801.

Yours faithfully,

Rob Zimmerman

Notalot,
Wishing you a full and speedy recovery, all the very best mate.

Very happy after the shenanigans of the last few days. Would we be getting an official announcement about going into clinic?

Still scratching my head on that one.

On c19

The timing of c19 will be determined once consultations have taken place. It don’t say 2022 anywhere.

The Rns states…
“The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.”
“Timing and design of the trials” says to me this is progressing rapidly, experts in the covid field are being consulted. It can’t be long before Sar announce what way they want to go with this either gov aid or alone, I believe Sar must be in the driving seat.

Add to that Tim’s statement
“ We are particularly pleased to have raised substantial additional funding during the period, which will be deployed to advance these programmes into clinical development and build a robust data package to support our ongoing partnering activities for these exciting and differentiated assets."

“Exiting, Differentiated assets”

Says it all,

Hi Stoney, perhaps this statement today “ The timing and design of the clinical trials for Covid-19 applications will be determined following consultations with experts in the field.” Experts in the field are in consultation with Tim & John surely progress will be fast tracked on C19. Can’t be long before the next announcement.

How would you think our HNWI have reacted to today’s trading update or indeed the way it has been laid out, I hope they have made contact and in no uncertain terms explained how they would like to see further announcements properly proof read so they can only be interpreted exactly how they were meant to be. Let’s hope lessons have been learnt and some better articulate authors are used in the future. After all we are now in a fast moving process, HNWIs won’t stand for schoolboy errors. Onwards and upwards. GLALTHs.

Or is this MMs trick to bring us down to swoop up stop loses’s. Nothing in the RNS that we never knew. LTHs will hopefully see SP return to normality soon.

We just need the news to flow then we will all be buzzing. Take this as the clam before the storm.
Keep positive until then fella’s

Sra737 was mentioned to be involved with both the above back in 2018. What happened?
https://www.thetimes.co.uk/article/glaxo-hits-back-in-astra-zeneca-row-90s09vgbj

And once it comes and hits us hard, I’m thinking of leaving at least 20% of my shares in SAR.
Any one else thinking likewise or would you sell the lot? I know some of us plan to sell in batches.
Interesting to hear other’s thoughts.
Thanks.

How. many more hnwi batches can we stand before it affects the LTH price expectations? Someone said the first one was 1% of the market cap, I believe that was the 2.8 in early June. Is there a limit of do we just welcome any one with deep pockets onboard.